Last reviewed · How we verify
JS001 and JS004 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
JS001 and JS004 (JS001 and JS004) — Shanghai Junshi Bioscience Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JS001 and JS004 TARGET | JS001 and JS004 | Shanghai Junshi Bioscience Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JS001 and JS004 CI watch — RSS
- JS001 and JS004 CI watch — Atom
- JS001 and JS004 CI watch — JSON
- JS001 and JS004 alone — RSS
Cite this brief
Drug Landscape (2026). JS001 and JS004 — Competitive Intelligence Brief. https://druglandscape.com/ci/js001-and-js004. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing